Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

the standard of care. The study found:

-- Up to 81 percent of those patients treated with R1626 1500 mg (twice-

daily) + PEGASYS + COPEGUS had an undetectable HCV viral load by week

four (mean reduction of 5.2 log10 IU/mL)

-- ALT, a liver enzyme, normalized in approximately 50 percent of patients

in R1626 treatment groups

-- Most reported adverse events were mild to moderate. Dose dependent,

reversible grade four neutropenia was observed in the R1626 arms (36

percent in patients receiving R1626 1500 mg + PEGASYS + COPEGUS), and

was the main reason for dose reduction and discontinuation

Lack of Resistance

According to a second presentation at the conference, resistance to R1626 was not identified following intensive testing for either two weeks of treatment with R1626 as monotherapy, or in patients treated with R1626 for four weeks in combination with the standard of care. These findings suggest that there is a high barrier to the development of resistance to R1626 in vivo.

Start of Phase IIb Trial

R1626 is being progressed into Phase IIb study, called POLI 1, to further investigate the new treatment regimens of R1626, in combination with standard or lower dose of PEGASYS and standard dose of COPEGUS. This Phase IIb trial is now open and enrolling patients in eight countries, including the United States. More information about R1626 and the clinical studies can be found on http://www.roche-trials.com.

"As a clinician, I am excited by the high rates of viral negativity that were observed after four weeks of treatment with R1626 in combination with the standard of care. The design of the Phase IIb study should enable us to find the doses of R1626, PEGASYS and COPEGUS that achieve the appropriate balance between safety and efficacy," said Dr. David Nelson, Director of Hepatology and Liver Transplantation at the
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014 Galmed Pharmaceuticals Ltd. ... biopharmaceutical company focused on the development and commercialization ... of liver diseases and cholesterol gallstones, announced today ... the FDA, approved its request for Fast Track ... treatment of Non-Alcoholic Steato-Hepatitis, or NASH.  ...
(Date:9/23/2014)... N.J. , Sept. 23, 2014  MEDIMETRIKS ... and William Resnick have been elected ... Mr. Lary, who will serve ... financial and investment experience to the Company.  Mr. ... Capital Advisors, LLC, a leading institutional investment firm.  ...
(Date:9/23/2014)... YORK , Sept 23, 2014  Vesselon, Inc. ... its Board of Directors, effective September 15, 2014. Dr. ... Inc. as its placement agent to market a private ... immediate and early stroke treatment. "Jurgen,s deep ... will be a great asset to Vesselon as we ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3
... May 16, 2011 Volcano Corporation (NASDAQ: VOLC ... Revascularization (EuroPCR) from May 17 – 20. Volcano,s focus will ... includes innovative devices like the Vascular Imaging Balloon Catheter (VIBE® ... use and value of Precision Guided Therapy in clinical practice ...
... PITTSBURGH, May 13, 2011 Mylan Inc. (Nasdaq: ... Pharmaceuticals Inc. has launched Cyclobenzaprine Hydrochloride (HCl) Extended-release (ER) ... first company to have filed a substantially complete ANDA ... Capsules and was awarded 180 days of marketing exclusivity. ...
Cached Medicine Technology:Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR 2Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR 3Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR 4
(Date:9/23/2014)... World of Home Fitness is committed to supporting ... gym has been raising money to support Meals on ... World of Home Fitness has participated in and raised ... summer, World of Home Fitness raised more than $600 ... participants helped feed seniors "one rep at a time." ...
(Date:9/23/2014)... From first-hand experience, Matthew O'Farrell knows ... how it can be treated. , A medically retired ... 2006. His platoon sustained multiple attacks resulting in five ... with combat-related PTSD and honorably discharged from the Army. ... had distanced myself from my friends and family,” recalled ...
(Date:9/23/2014)... San Diego, CA (PRWEB) September 23, 2014 ... website daily regarding all the latest information from the ... announced on September 5, that its Private Label Jalapeno ... glass and small stones. Publix Jalapeno Bagels ... in the bakery department. , Taking into consideration ...
(Date:9/23/2014)... As a consumer in today’s world, ... It’s difficult to trust testimonials that are supplied by ... manipulate their customers into saying anything. , Consumer advocacy ... to lack in depth coverage on a particular market ... to fix this issue and focus on exposing the ...
(Date:9/23/2014)... TX (PRWEB) September 23, 2014 Dr. Connie ... her medical practices to new office space at 12200 Park ... Located at the office will be Park Cities Aesthetics, Optimal ... , In announcing her move, Dr. Casad said, “The ... what treatment they select, we want them to always feel ...
Breaking Medicine News(10 mins):Health News:World of Home Fitness Supports Meals on Wheels 2Health News:Virtual Reality software to help treat PTSD 2Health News:Virtual Reality software to help treat PTSD 3Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Consumer Health Reports Debuts Revolutionary Review Website 2Health News:Dr. Connie Casad Moving to New Office Location 2
... BIRMINGHAM, Ala. Leading high-performance computing engineers and ... University of Alabama at Birmingham (UAB) have called ... group says growing world-wide computer use puts more ... projects that are stored digitally at risk for ...
... lanes could protect more riders, researchers say , WEDNESDAY, Oct. ... and longer hospital stays, with both worsening over the past ... results of a study of biking injuries. , Chest injuries ... last five years, the study authors found. Cyclists themselves appear ...
... , MENLO PARK, Calif., Oct. 14 New Enterprise Associates, ... that Ravi Viswanathan, PhD, has been promoted to General Partner. ... on energy and growth equity information technology investments, as well ... Frank Torti, MD, to Principal. Dr. Torti joined NEA in ...
... ... industry, announced the addition of certain providers of Sistemas Medicos Nacionales, S.A. de C.V. (SIMNSA) ... ... a global health care company in the emerging medical tourism industry, announced the addition of ...
... As the leaves begin to change color and ... today announced the launch of "A BETTER BEDTIME," its 2009-2010 ... campaign is based online at the Official Pajama Program A ... , Pajama Program provides new pajamas and new books to ...
... a third of deaths, study finds, , WEDNESDAY, Oct. 14 (HealthDay ... who share a bed or sofa with a parent, and alcohol ... many of the cases, says a U.K. study. , Researchers analyzed ... between January 2003 and December 2006. Of the deaths, 54 percent ...
Cached Medicine News:Health News:UAB international conference focuses on preventing high-capacity computer data theft 2Health News:As More Cyclists Hit the Road, Serious Injuries Rise 2Health News:NEA Promotes Ravi Viswanathan to General Partner and Names Frank Torti to Principal Post 2Health News:NEA Promotes Ravi Viswanathan to General Partner and Names Frank Torti to Principal Post 3Health News:SIMNSA is added to the Satori Global Network™ in Mexico to Offer U.S. Employers Cross Border Health Benefit Options 2Health News:Pajama Program Launches 2009-2010 Awareness & Fundraising Campaign: 'A BETTER BEDTIME' 2Health News:Pajama Program Launches 2009-2010 Awareness & Fundraising Campaign: 'A BETTER BEDTIME' 3Health News:Pajama Program Launches 2009-2010 Awareness & Fundraising Campaign: 'A BETTER BEDTIME' 4Health News:Shared Bed May Raise SIDS Risk 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: